COVID-19 Clinical Trials in Chicago

Showing 41-60 of 145 trials

Study to AntagOnize Plasminogen Activator Inhibitor-1 in Severe COVID-19

NCT04634799

This is a single-center, randomized double blind placebo controlled trial to evaluate the efficacy and safety of novel PAI-1 inhibitor (TM5614) for high-risk patients hospitalized with severe COVID-19 at Northwestern Memorial Hospital. The patients will be randomized in a 1:1 ratio to receive standard of care plus TM5614 or standard of care plus placebo.

Covid19

Northwestern University9 participantsStarted Jan 2021

Chicago, Illinois, United States

COMPLETEDPhase 2/32.2 miles

Study of Mavrilimumab (KPL-301) in Participants Hospitalized With Severe Corona Virus Disease 2019 (COVID-19) Pneumonia and Hyper-inflammation

NCT04447469

Interventional, randomized, double-blind, placebo-controlled study encompassing 2 development phases (Phase 2 and Phase 3).

COVID

Kiniksa Pharmaceuticals International, plc814 participantsStarted Jul 2020

Los Angeles, California, United States • San Diego, California, United States • Chicago, Illinois, United States +29 more locations

Study to AntagOnize Plasminogen Activator Inhibitor-1 in Severe COVID-19

Study of Mavrilimumab (KPL-301) in Participants Hospitalized With Severe Corona Virus Disease 2019 (COVID-19) Pneumonia and Hyper-inflammation

COVID-19 Trials in Other Cities

Phase III Double-blind, Placebo-controlled Study of AZD7442 for Pre-exposure Prophylaxis of COVID-19 in Adult.

Evaluation of the RD-X19 Treatment Device in Individuals With Mild COVID-19

A Randomized, Open-label, Dose-ranging Study in Adults and Pediatric Individuals ≥ 12 Years of Age to Assess the Safety, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of AZD7442, for Pre-exposure Prophylaxis of COVID-19

Study of Monovalent and Bivalent Recombinant Protein Vaccines Against COVID-19 in Adults 18 Years of Age and Older

A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

Covid-19 Infection and Pulmonary Distress Treatment With Zanubrutinib in Hospitalized Participants

COVID-19 IgG Formation in Physicians at ALGH and Their Household Members

A Study to Investigate the Prevention of COVID-19 WithVYD222 in Adults with Immune Compromise and in Participants Aged 12 Years or Older Who Are At Risk of Exposure to SARS-CoV-2

Novel Experimental COVID-19 Therapies Affecting Host Response

COVID-19 Vaccine Response in Sickle Cell Disease

A Study of Ad26.COV2.S in Adults (COVID-19)

Utilizing Novel Blood RNA Biomarkers as a Diagnostic Tool in the Identification of Long COVID-19

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibody BGB-DXP593 in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)

Study to Evaluate Safety and Immunogenicity of COVID-19 Vaccine in Children 6 Months to < 12 Years

Safety and Immunogenicity of RNA-based Vaccines Against SARS-CoV-2 Variants in Healthy Participants

Multiple Dosing of Mesenchymal Stromal Cells in Patients With ARDS (COVID-19)

Engaging Staff to Improve COVID-19 Vaccination Response at Long-Term Care Facilities

Other Conditions in Chicago